AR and neoplasm: GSK805 was demonstrated to be effective in suppression of Th17 cell differentiation via antagonizing RORγt26, while XY018 was shown to strongly inhibit the growth of androgen receptor-positive prostate tumors via inhibition of tumor cell RORγ27.